Business
CURE Pharma Looks to Revolutionize Cannabinoid Delivery
CURE Pharma Looks to Revolutionize Cannabinoid Delivery.
About this update from Avenir Wellness Solutions Inc.
[{"type":"text","content":"\n \n \n CURE Pharma Looks to Revolutionize Cannabinoid Delivery\n \n \nCURE Pharma Looks to Revolutionize Cannabinoid Delivery\n \n SEATTLE, WA--(Marketwired - Jun 15, 2017) - CFN Media Group (\"CFN Media\"), the leading agency and digital media network dedicated to legal cannabis, today announced publication of an article covering CURE Pharmaceutical Inc.'s (OTCQB: CURR) Oral Thin Film technology and why it could be a game-changer in the cannabis industry.\n Many successful pharmaceutical products rely on both efficacious chemical compounds and an effective delivery system. While many companies outsource one or the other, there are some companies that have developed both pieces of the puzzle, which enables them to rapidly bring successful products to market without diluting ownership. These companies also have the ability to generate licensing revenue through deals with third parties.\n Oral Thin Film Technology\n CURE Pharma's CureFilm™ is a patented multi-layer oral thin film designed to improve the pharmacokinetic profile and overall therapeutic index of active pharmaceutical ingredients (APIs). The product can be administered without water to the tongue, cheek, or sublingual regions of the mouth and enables medications to enter the bloodstream enterically, buccally, or sublingually for maximum dosage while providing better flavor masking than other formulations.\n The technology has many advantages over other delivery systems. CureFilm™ is more stable, durable, and faster acting than other oral delivery mechanisms. Greater palatability improves medication adherence and increased bioavailability helps maximize the effectiveness of APIs. The product requires no water to administer making it easier to take, particularly for children, elderly patients, animals, and others that may have trouble swallowing pills. In fact, the Harris Institute did a study that shows that 40% of adults have trouble swallowing pills, creating a huge market for a substitute to traditional pills. \n The delivery technology can be applied to many different pharmaceuticals, which makes it a compelling \"platform play\" for investors. For instance, pharmaceutical companies facing near-term patent expirations may leverage the new delivery technology as a way to extend patent life by reformulating products. The drug companies benefit from...